Ronak

Patient Details

Roniscan®

Generic Name: Gadodiamide
Dosage Form: Injectable solution containing 287 mg/mL of gadodiamide
Drug Class: Gadolinium-based contrast agent
Indications: Roniscan® is used for MRI of the central nervous system, chest (non-cardiac), abdomen, pelvis, and retroperitoneal space to enhance lesion visibility.

Roniscan®

Roniscan® (Gadodiamide) is a contrast agent that, when placed in an external magnetic field, generates magnetic effects in the target tissue, enabling high-quality imaging.

Indications for Roniscan®

Magnetic Resonance Imaging (MRI) of the central nervous system, chest (non-cardiac), abdomen, pelvis, and retroperitoneal space
Magnetic Resonance Angiography (MRA)
Musculoskeletal imaging

Dosage Form

Vial containing 15 mL injectable solution (287 mg/mL)

Preparation of Roniscan®

Roniscan® is a ready-to-use solution; no preparation is needed.

Administration and Dosage of Roniscan®

IV only: Do not administer intrathecally; may cause sensory/motor nerve damage, seizures, or coma.
Solution is colorless to pale yellow; inspect for discoloration or particulate matter before use. Do not use if particles or color changes are observed.
Use the solution immediately after drawing it into a syringe; discard any remaining solution.
Optionally, follow with 5 mL of 0.9% sodium chloride to ensure complete administration.
Imaging should be completed within 1 hour after injection.
Following administration in musculoskeletal imaging, the injection site was flushed with 40 mL NS.

Monitoring Requirements During Roniscan® Therapy

Signs of hypersensitivity during and shortly after injection
Kidney function (prior to contrast administration)
Short- and long-term monitoring for nephrogenic systemic fibrosis (NSF): itching, swelling, skin tightening, joint stiffness, pelvic or rib bone pain, muscle weakness
Pregnancy status before use

Contraindications

Hypersensitivity to gadodiamide or any component of the formulation
Acute or chronic severe kidney failure (GFR <30 mL/minute/1.73 m²
Neonates up to 4 weeks of age (due to their immature renal function).

Warnings and Precautions

In patients with kidney impairment, inflammatory diseases, pregnant women, and children, gadolinium may remain longer in the body; use the minimum necessary for imaging.
Gadolinium-based agents may increase the risk of nephrogenic systemic fibrosis (NSF); use only when essential and when an MRI without contrast cannot provide sufficient diagnostic information.
Patients should be closely monitored during and for a few hours after injection, especially those with drug allergies, asthma, or other allergic conditions. Stop injection and initiate treatment immediately if severe allergic reactions occur (skin, respiratory, cardiovascular).
Creatinine clearance should be calculated for patients at risk of reduced kidney function (e.g., age >60, hypertension, diabetes) and dosing decisions made accordingly.

Use During Pregnancy and Breastfeeding

Consult a physician before use during pregnancy or breastfeeding.
Gadodiamide may cross the placenta; use only if the benefits outweigh potential fetal risks.
Gadodiamide may be excreted in breast milk; decisions on use should consider maternal benefit vs. potential risk to the infant.

Side Effects of Roniscan®

Possible side effects (not all patients experience these):

Headache and dizziness
Abdominal pain, nausea, or vomiting
Local injection site reactions
Shortness of breath

Drug Interactions

Consult a doctor or pharmacist before using Roniscan® with other medications or supplements.

Packaging

Each package contains 1 vial of Roniscan®.

Storage

Store below 25°C, protected from light and moisture.
Protect from freezing.
Use by the expiration date; do not use expired products.
Keep out of reach of children.
Keep in the original packaging until use.

References

Gadodiamide: Drug information, UpToDate 2025
Drugs.com – Gadodiamide